HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
Clinical trial NCT06792825 · RECRUITING
Trial details
- NCT number
- NCT06792825
- Sponsor
- Masonic Cancer Center, University of Minnesota
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-07
- Primary completion
- 2029-07-08
- Enrollment
- 65
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.